Podcasts about global oncology academy

Host: Jacob Sands, MD Guest: Elaine Shum, MD Guest: Estelamari Rodriguez, MD, MPH There was a recent pooled analysis of the TROPION-Lung01 and TROPION-Lung05 studies, which focused on the efficacy and safety of datopotamab deruxtecan (Dato-DXd) in patients with previously treated EGFR-mutated advanced non-small cell lung cancer (NSCLC). According to the results, Dato-DXd demonstrated an overall response rate of 43 percent, with durable responses and a manageable safety profile. Joining Dr. Jacob Sands to talk more about these findings and their implications are Drs. Elaine Shum and Estelamari Rodriguez. Dr. Shum is an Assistant Professor in the Department of Medicine at NYU Grossman School of Medicine, and Dr. Rodriguez is an Associate Director of Community Outreach, Thoracic Oncology at Sylvester Comprehensive Cancer Center at the University of Miami Health System.

Host: Gerard A. Silvestri MD, MS, Master FCCP Guest: Anurag Singh, MD Guest: Adam H. Fox, MD, MSc Guest: Mariam Alexander, MD, PhD Despite the typically poor prognosis of extensive-stage small cell lung cancer, recent advancements are reshaping clinical perspectives on treatment. New and emerging options show promise for prolonged survival and improved quality of life. Join Drs. Gerard Silvestri, Adam Fox, Mariam Alexander, and Anurag Singh as they discuss how the therapeutic landscape is evolving for these patients. Silvestri is a pulmonologist and the Hillenbrand Professor of Thoracic Oncology at the Medical University of South Carolina. Dr. Fox is a pulmonologist and Assistant Professor of Medicine at the Medical University of South Carolina. Dr. Alexander is a medical oncologist and Assistant Professor of Medicine at the Medical University of South Carolina. Dr. Singh is a Professor of Radiation Oncology and the Director of Radiation Research at the Roswell Park Cancer Center in New York. This program is produced in partnership with the American College of Chest Physicians and is sponsored by AstraZeneca.

Host: Gerard A. Silvestri MD, MS, Master FCCP Guest: Anurag Singh, MD Guest: Adam H. Fox, MD, MSc Guest: Mariam Alexander, MD, PhD Recent therapeutic advances are reshaping our approach to limited-stage small cell lung cancer. In this multidisciplinary discussion, Dr. Gerard Silvestri sits down with Drs. Adam Fox, Mariam Alexander, and Anurag Singh to explore the evolving standard of care and practical considerations for timely and effective care. Dr. Silvestri is a pulmonologist and the Hillenbrand Professor of Thoracic Oncology at the Medical University of South Carolina. Dr. Fox is a pulmonologist and Assistant Professor of Medicine at the Medical University of South Carolina. Dr. Alexander is a medical oncologist and Assistant Professor of Medicine at the Medical University of South Carolina. Dr. Singh is a Professor of Radiation Oncology and the Director of Radiation Research at the Roswell Park Cancer Center in New York. This program is produced in partnership with the American College of Chest Physicians and is sponsored by AstraZeneca.

Guest: Laura Cappelli, MD, MHS,MS Patients who are receiving immunotherapy for cancer sometimes develop significant autoimmune complications, which can be fatal. Join Dr. Laura Cappelli, Associate Professor of Medicine and Oncology at the Johns Hopkins University School of Medicine, as she explains how multidisciplinary collaboration can help manage these rheumatic immune-related adverse events (irAEs). Dr. Cappelli also spoke about this topic at the 2025 Congress of Clinical Rheumatology East conference.

Guest: Ihtisham Ahmad Preclinical findings in animal models have shown that activating cannibinoid receptors can shrink prostate tumors in animal models. To explore whether these effects translate to human populations, a recent study examined a potential link between cannabis use and the development of prostate cancer. Hear from Ihtisham Ahmad, a fourth-year medical student at the University of Toronto, as he explains the methodology and findings from his research, which he presented at the American Urological Association 2025 Annual Meeting.

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Matthew Hadfield, MD Subcutaneous cancer immunotherapies may offer a faster, more resource-efficient alternative to intravenous administration, improving patient convenience and accessibility while maintaining efficacy. However, careful monitoring for immunotherapy-related toxicities remains essential. Joining Dr. Charles Turck to discuss these key considerations for subcutaneous cancer immunotherapies is Dr. Matthew Hadfield, Assistant Professor of Medicine at Brown University/Alpert School of Medicine.

Guest: Lauren Schaff, MD Glioblastomas are fast, aggressive, and resistant to many standard therapies. Dr. Lauren Schaff, a neuro-oncologist at Memorial Sloan Kettering Cancer Center, explains how new molecular understandings and treatment avenues are paving the way for a more personalized, hopeful approach to care.

Guest: Lauren Schaff, MD Glioblastomas are fast, aggressive, and resistant to many standard therapies. Dr. Lauren Schaff, a neuro-oncologist at Memorial Sloan Kettering Cancer Center, explains how new molecular understandings and treatment avenues are paving the way for a more personalized, hopeful approach to care.

Guest: Lauren Schaff, MD Glioblastomas are fast, aggressive, and resistant to many standard therapies. Dr. Lauren Schaff, a neuro-oncologist at Memorial Sloan Kettering Cancer Center, explains how new molecular understandings and treatment avenues are paving the way for a more personalized, hopeful approach to care.

CME credits: 1.00 Valid until: 21-11-2026 Claim your CME credit at https://reachmd.com/programs/cme/DefiningtheStandardofCareandOptimalSequencinginBRAFMutantmCRcSecondLineandBeyond/32944/ In this series, Dr. Fortunato Ciardiello and Dr. Jenny Seligmann review the management of metastatic colorectal cancer (mCRC), with a focus on timing and methodology of molecular testing, targeted treatment combinations for BRAF-mutant mCRC, the management of treatment-related adverse events.

CME credits: 1.00 Valid until: 21-11-2026 Claim your CME credit at https://reachmd.com/programs/cme/CaseConsultAdverseEffectMonitoringManagementandMitigationDuringTargetedTherapyforBRAFMutantmCRc/33134/ In this series, Dr. Fortunato Ciardiello and Dr. Jenny Seligmann review the management of metastatic colorectal cancer (mCRC), with a focus on timing and methodology of molecular testing, targeted treatment combinations for BRAF-mutant mCRC, the management of treatment-related adverse events.

CME credits: 1.00 Valid until: 21-11-2026 Claim your CME credit at https://reachmd.com/programs/cme/ProactiveAdverseEffectManagementinmCRCImprovingTolerabilitytoOptimizePatientOutcomes/32945/ In this series, Dr. Fortunato Ciardiello and Dr. Jenny Seligmann review the management of metastatic colorectal cancer (mCRC), with a focus on timing and methodology of molecular testing, targeted treatment combinations for BRAF-mutant mCRC, the management of treatment-related adverse events.

CME credits: 1.00 Valid until: 21-11-2026 Claim your CME credit at https://reachmd.com/programs/cme/MutationalTestinginmCRcMethodsandDataDrivingTreatmentSelection/32942/ In this series, Dr. Fortunato Ciardiello and Dr. Jenny Seligmann review the management of metastatic colorectal cancer (mCRC), with a focus on timing and methodology of molecular testing, targeted treatment combinations for BRAF-mutant mCRC, the management of treatment-related adverse events.

CME credits: 1.00 Valid until: 21-11-2026 Claim your CME credit at https://reachmd.com/programs/cme/from-guidelines-to-practice-first-line-treatment-choices-in-mcrc/32943/ In this series, Dr. Fortunato Ciardiello and Dr. Jenny Seligmann review the management of metastatic colorectal cancer (mCRC), with a focus on timing and methodology of molecular testing, targeted treatment combinations for BRAF-mutant mCRC, the management of treatment-related adverse events.

Host: Peter Buch, MD, FACG, AGAF, FACP Guest: Aasma Shaukat, MD, MPH While fecal immunochemical testing and multitarget stool DNA testing are commonly used to screen for colon cancer, screening rates remain low throughout the United States. With the introduction of blood-based testing modalities, noninvasive colon cancer screening is becoming more accessible than ever. Join host Dr. Peter Buch and Dr. Aasma Shaukat as they discuss the effectiveness of current and emerging methods as well as best practices for screening patients. Dr. Shaukat is the Robert M. and Mary H. Glickman Professor of Medicine at the NYU Grossman School of Medicine and the Co-Director of Translational Research, Education, and Careers and the Director of Outcomes Research in the Division of Gastroenterology and Hepatology at NYU.

CME credits: 1.00 Valid until: 14-03-2026 Claim your CME credit at https://reachmd.com/programs/cme/collaborative-insights-to-solve-the-puzzle-of-bladder-cancer/30062/ This online educational activity, derived from a live satellite symposium at ASCO GU 2025, explores innovative strategies for personalized care in bladder cancer. Participants will gain a deeper understanding of molecular targets and profiling methodologies, review cutting-edge clinical trial evidence, and examine the latest advances in therapy delivery. The program also focuses on creating effective, evidence-based treatment plans and strategies for sequencing molecularly targeted therapies, as well as integrating interprofessional protocols for managing adverse events. This collaborative approach will equip learners with practical insights to enhance treatment outcomes in bladder cancer. =

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Anthony Stein, MD Could a novel triplet combination therapy offer a new path forward in acute myeloid leukemia (AML) treatment? A recent Phase 1B trial explored the potential of tagraxofusp, azacitidine, and venetoclax for AML patients. To discuss the findings on this triplet combination therapy, Dr. Charles Turck speaks with Dr. Anthony Stein, Professor in the Department of Hematology and Hematopoietic Cell Transplantation at City of Hope in Duarte, California.

Host: Jennifer Caudle, DO Guest: Naval Daver, MD Not only is CD123 one of the most common antigens expressed on the surface of acute myeloid leukemia (AML) tumors, but it's also associated with more proliferative disease that's resistant to standard therapies. Given its prevalence and potential implications, a number of different CD123-targeting approaches are under investigation, including antibody-drug conjugates, bi-specific antibodies, fusion protein, and CAR T-cell therapy. In light of these new approaches, Dr. Jennifer Caudle and Dr. Naval Daver discuss the importance of targeting CD123 in AML. Dr. Daver is a Professor and Director of the Leukemia Research Alliance Program in the Department of Leukemia at MD Anderson Cancer Center in Houston.

CME credits: 0.25 Valid until: 13-01-2026 Claim your CME credit at https://reachmd.com/programs/cme/diagnosis-and-management-of-metastatic-pdac/26434/ Pancreatic ductal adenocarcinoma, otherwise known as PDAC, is a lethal disease which is usually diagnosed at an advanced stage and has an extremely poor prognosis. Advancements in treatment regimens have improved survival rates, but early diagnosis is crucial for improving outcomes and awareness of risk factors is vital for early diagnosis. Cytotoxic chemotherapy is the cornerstone of treatment for advanced or metastatic cases, although molecularly targeted therapies and immunotherapies may benefit select patients. Treatment selection depends on several factors, including patients' performance status and co-morbidities and these should be considered alongside the efficacy and safety profiles of the different chemotherapy regimens. This 2-part microlearning provides an overview of the risk factors, diagnostic tools and treatment options available to date for different patient groups. Complete both modules, answer pre- and post-test questions and start earning CME credits. This programme is also featured on the COR2ED website, here: Metastatic pancreatic ductal adenocarcinoma (PDAC): from diagnosis to treatment

CME credits: 0.25 Valid until: 13-01-2026 Claim your CME credit at https://reachmd.com/programs/cme/chemotherapy-strategies-for-metastatic-pdac/26435/ Pancreatic ductal adenocarcinoma, otherwise known as PDAC, is a lethal disease which is usually diagnosed at an advanced stage and has an extremely poor prognosis. Advancements in treatment regimens have improved survival rates, but early diagnosis is crucial for improving outcomes and awareness of risk factors is vital for early diagnosis. Cytotoxic chemotherapy is the cornerstone of treatment for advanced or metastatic cases, although molecularly targeted therapies and immunotherapies may benefit select patients. Treatment selection depends on several factors, including patients' performance status and co-morbidities and these should be considered alongside the efficacy and safety profiles of the different chemotherapy regimens. This 2-part microlearning provides an overview of the risk factors, diagnostic tools and treatment options available to date for different patient groups. Complete both modules, answer pre- and post-test questions and start earning CME credits. This programme is also featured on the COR2ED website, here: Metastatic pancreatic ductal adenocarcinoma (PDAC): from diagnosis to treatment

Guest: Efrat Dotan, MD Guest: Shubham Pant, MD, MBBS Pancreatic ductal adenocarcinoma, otherwise known as PDAC, is a lethal disease which is usually diagnosed at an advanced stage and has an extremely poor prognosis. Advancements in treatment regimens have improved survival rates, but early diagnosis is crucial for improving outcomes and awareness of risk factors is vital for early diagnosis. Cytotoxic chemotherapy is the cornerstone of treatment for advanced or metastatic cases, although molecularly targeted therapies and immunotherapies may benefit select patients. Treatment selection depends on several factors, including patients' performance status and co-morbidities and these should be considered alongside the efficacy and safety profiles of the different chemotherapy regimens. This 2-part microlearning provides an overview of the risk factors, diagnostic tools and treatment options available to date for different patient groups. Complete both modules, answer pre- and post-test questions and start earning CME credits. This programme is also featured on the COR2ED website, here: Metastatic pancreatic ductal adenocarcinoma (PDAC): from diagnosis to treatment

Guest: Efrat Dotan, MD Guest: Shubham Pant, MD, MBBS Pancreatic ductal adenocarcinoma, otherwise known as PDAC, is a lethal disease which is usually diagnosed at an advanced stage and has an extremely poor prognosis. Advancements in treatment regimens have improved survival rates, but early diagnosis is crucial for improving outcomes and awareness of risk factors is vital for early diagnosis. Cytotoxic chemotherapy is the cornerstone of treatment for advanced or metastatic cases, although molecularly targeted therapies and immunotherapies may benefit select patients. Treatment selection depends on several factors, including patients' performance status and co-morbidities and these should be considered alongside the efficacy and safety profiles of the different chemotherapy regimens. This 2-part microlearning provides an overview of the risk factors, diagnostic tools and treatment options available to date for different patient groups. Complete both modules, answer pre- and post-test questions and start earning CME credits. This programme is also featured on the COR2ED website, here: Metastatic pancreatic ductal adenocarcinoma (PDAC): from diagnosis to treatment

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Matthew Matasar, MD When treating relapsed or refractory large B-cell lymphoma (R/R LBCL) with CAR T-cell therapy, the risk of adverse events is a key consideration. Models such as PhasED-Seq and CAR-HEMATOTOX can help clinicians assess the patient's risk and personalize care plans regarding treatment selection and location, prophylactic regimen, and early intervention strategies. Tune in to hear Dr. Charles Turck and Dr. Matthew Matasar discuss the importance of these models in identifying individual factors, which can maximize the benefits of CAR T-cell therapy and reduce toxicities. Dr. Matasar is the Chief of the Division of Blood Disorders at Rutgers Cancer Institute and a Professor of Medicine at Rutgers Robert Wood Johnson Medical School.

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Sairah Ahmed, MD Guest: Caron A. Jacobson, MD The side effects associated with CAR T-cell therapy are very different than those seen with other cancer therapies and include cytokine-release syndrome (CRS) and neurotoxicity. It's important to know how to recognize the signs of these adverse events and treat patients with relapsed or refractory large B-cell lymphoma early to avoid drastic quality-of-life impacts. To help improve patient safety and decrease hospital utilization, Dr. Charles Turck speaks with Drs. Caron Jacobson and Sairah Ahmed about the proper identification and management of these side effects in patients receiving CAR T-cell therapy. Dr. Jacobson is the Medical Director of the Immune Effector Cell Therapy Program at Dana-Farber Cancer Institute in Boston, and Dr. Ahmed is an Associate Professor in the Department of Lymphoma and Myeloma Division of Cancer Medicine at the University of Texas MD Anderson Cancer Center in Houston.

Host: Jacob Sands, MD Guest: Julia Rotow, MD In non-squamous non-small cell lung cancer (NSCLC), a small percentage of patients will have activating HER2 mutations. For these patients, the standard second-line therapy is docetaxel, but this can have poor response rates. That's why the DESTINY-Lung03 trial examined the safety and efficacy of trastuzumab deruxtecan in patients with pretreated HER2-overexpressing non-squamous NSCLC. Here with Dr. Jacob Sands to share the findings from part 1 of this trial is thoracic medical oncologist Dr. Julia Rotow.

Guest: Tara Graff, DO, MS Host: Charles Turck, PharmD, BCPS, BCCCP While CAR T-cell therapy is an effective option for patients with certain blood cancers like lymphoma and myeloma, it's associated with two common adverse events: cytokine release syndrome and neurotoxicity. Given those risks, safety protocols have evolved over time to include strategies like aggressive hydration, prophylactic use of corticosteroids, early intervention with tocilizumab, and multidisciplinary care. Joining Dr. Charles Turck to share her insights into how we can lower the risks of CAR T-cell therapy is Dr. Tara Graff, a medical oncologist who leads a community-based clinical trial program at Mission Cancer and Blood in Des Moines, Iowa.

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Laura Alder, MD The recent approval of antibody drug conjugates (ADCs) has the potential to address unmet needs associated with second-line treatment options for non-small cell lung cancer, like limited benefits and substantial toxicity. But given the complex structure of ADCs, it's important to identify biomarkers that can predict a patient's response to therapy. That's why the phase 1b TROPION-LUNG02 trial examined the effectiveness of Dato-DXd and HER3-DXd in the presence of predictive biomarkers. Joining Dr. Charles Turck to discuss the trial's findings and implications is Dr. Laura Alder, Assistant Professor of Medicine at Duke University School of Medicine in Durham, North Carolina.

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Thomas Egenod, MD In an effort to identify additional treatment options for resectable non-small cell lung cancer (NSCLC), the NeoCOAST-2 study is evaluating the efficacy and safety of combining durvalumab, chemotherapy, and novel agents in the neoadjuvant setting as well as combining durvalumab with novel agents in the adjuvant setting. Joining Dr. Charles Turck to share the preliminary results regarding the safety, pathological complete response, and major pathological response rates of these two approaches is study investigator Dr. Thomas Egenod, who presented the NeoCOAST-2 study at the 2024 World Conference on Lung Cancer.

Host: Jacob Sands, MD Guest: Alex Spira, MD, PhD, FACP Valemetostat is a novel therapy that's demonstrated clinical efficacy and safety across multiple hematologic malignancies, but what role might it have in treating patients with advanced, unresectable, or metastatic non-squamous non-small cell lung cancer (NSCLC)? To find out, an upcoming trial is examining the efficacy and safety of combining valemetostat and datopotamab deruxtecan (Dato-DXd). Here with Dr. Jacob Sands to talk about the study's design and next steps is Dr. Alex Spira, Director of the Thoracic and Phase I Program at Virginia Cancer Specialists Research Institute and a Clinical Assistant Professor at Johns Hopkins.

Host: Jacob Sands, MD Guest: Aaron Lisberg, MD Unfortunately, brain metastases are very common in patients with non-small cell lung cancer (NSCLC). That's why the phase 3 TROPION-Lung01 trial examined the efficacy and safety of datopotamab deruxtecan (Dato-DXd) for advanced non-squamous NSCLC with brain metastases. Joining Dr. Jacob Sands to share the results presented at the 2024 ESMO Congress is thoracic medical oncologist Dr. Aaron Lisberg.

Host: Jacob Sands, MD Guest: Aaron Lisberg, MD Docetaxel alone or in combination with ramucirumab is the current standard of care for the second-line treatment of non-small cell lung cancer (NSCLC), but there are several limitations of docetaxel-containing regimens. That's why there's interest in identifying new therapies like datopotamab deruxtecan (Dato-DXd), which was found to improve overall survival based on an interim analysis. But what are the latest findings? Here to share the final overall survival data on Dato-DXd from the TROPION-Lung01 trial are Drs. Jacob Sands and Aaron Lisberg, who worked together on this research that was presented at the 2024 World Conference on Lung Cancer.

CME credits: 1.25 Valid until: 20-12-2025 Claim your CME credit at https://reachmd.com/programs/cme/incorporation-of-guideline-concordant-care-for-first-line-treatment-of-a-patient-with-metastatic-urothelial-carcinoma/29195/ This online CME activity, presented in collaboration with the National Comprehensive Cancer Network (NCCN®), focuses on translating oncology clinical practice guidelines into practical strategies for treating genitourinary malignancies. Participants will learn how to integrate clinical trial data into guideline-concordant first- and subsequent-line treatment plans for patients with metastatic urothelial cancer (UC), metastatic castration-resistant prostate cancer (mCRPC), and metastatic renal cell carcinoma (RCC). The program highlights the importance of evidence-based approaches and the use of immunotherapy and targeted therapies for advanced genitourinary malignancies. Attendees will also explore emerging data that could influence future treatment guidelines, patient case examples, and insights from international faculty to develop region-specific therapeutic strategies aligned with NCCN recommendations.

CME credits: 1.25 Valid until: 20-12-2025 Claim your CME credit at https://reachmd.com/programs/cme/insights-from-global-key-opinion-leaders-on-optimizing-patient-care-in-genitourinary-malignancies/29202/ This online CME activity, presented in collaboration with the National Comprehensive Cancer Network (NCCN®), focuses on translating oncology clinical practice guidelines into practical strategies for treating genitourinary malignancies. Participants will learn how to integrate clinical trial data into guideline-concordant first- and subsequent-line treatment plans for patients with metastatic urothelial cancer (UC), metastatic castration-resistant prostate cancer (mCRPC), and metastatic renal cell carcinoma (RCC). The program highlights the importance of evidence-based approaches and the use of immunotherapy and targeted therapies for advanced genitourinary malignancies. Attendees will also explore emerging data that could influence future treatment guidelines, patient case examples, and insights from international faculty to develop region-specific therapeutic strategies aligned with NCCN recommendations.

CME credits: 1.25 Valid until: 20-12-2025 Claim your CME credit at https://reachmd.com/programs/cme/guideline-recommendations-for-first-line-treatment-intensification-with-parp-inhibitor-combinations-in-patients-with-metastatic-castration-resistant-prostate-cancer/29196/ This online CME activity, presented in collaboration with the National Comprehensive Cancer Network (NCCN®), focuses on translating oncology clinical practice guidelines into practical strategies for treating genitourinary malignancies. Participants will learn how to integrate clinical trial data into guideline-concordant first- and subsequent-line treatment plans for patients with metastatic urothelial cancer (UC), metastatic castration-resistant prostate cancer (mCRPC), and metastatic renal cell carcinoma (RCC). The program highlights the importance of evidence-based approaches and the use of immunotherapy and targeted therapies for advanced genitourinary malignancies. Attendees will also explore emerging data that could influence future treatment guidelines, patient case examples, and insights from international faculty to develop region-specific therapeutic strategies aligned with NCCN recommendations.

CME credits: 1.25 Valid until: 20-12-2025 Claim your CME credit at https://reachmd.com/programs/cme/emerging-immunotherapy-combination-strategies-in-genitourinary-malignancies/29201/ This online CME activity, presented in collaboration with the National Comprehensive Cancer Network (NCCN®), focuses on translating oncology clinical practice guidelines into practical strategies for treating genitourinary malignancies. Participants will learn how to integrate clinical trial data into guideline-concordant first- and subsequent-line treatment plans for patients with metastatic urothelial cancer (UC), metastatic castration-resistant prostate cancer (mCRPC), and metastatic renal cell carcinoma (RCC). The program highlights the importance of evidence-based approaches and the use of immunotherapy and targeted therapies for advanced genitourinary malignancies. Attendees will also explore emerging data that could influence future treatment guidelines, patient case examples, and insights from international faculty to develop region-specific therapeutic strategies aligned with NCCN recommendations.

CME credits: 1.25 Valid until: 20-12-2025 Claim your CME credit at https://reachmd.com/programs/cme/clinical-evidence-driving-guideline-recommendations-for-monotherapy-in-the-second-line-or-later-setting-in-metastatic-urothelial-cancer/29194/ This online CME activity, presented in collaboration with the National Comprehensive Cancer Network (NCCN®), focuses on translating oncology clinical practice guidelines into practical strategies for treating genitourinary malignancies. Participants will learn how to integrate clinical trial data into guideline-concordant first- and subsequent-line treatment plans for patients with metastatic urothelial cancer (UC), metastatic castration-resistant prostate cancer (mCRPC), and metastatic renal cell carcinoma (RCC). The program highlights the importance of evidence-based approaches and the use of immunotherapy and targeted therapies for advanced genitourinary malignancies. Attendees will also explore emerging data that could influence future treatment guidelines, patient case examples, and insights from international faculty to develop region-specific therapeutic strategies aligned with NCCN recommendations.

CME credits: 1.25 Valid until: 20-12-2025 Claim your CME credit at https://reachmd.com/programs/cme/clinical-evidence-driving-guideline-recommendations-for-frontline-immunotherapy-based-combination-regimens-in-metastatic-urothelial-cancer/29193/ This online CME activity, presented in collaboration with the National Comprehensive Cancer Network (NCCN®), focuses on translating oncology clinical practice guidelines into practical strategies for treating genitourinary malignancies. Participants will learn how to integrate clinical trial data into guideline-concordant first- and subsequent-line treatment plans for patients with metastatic urothelial cancer (UC), metastatic castration-resistant prostate cancer (mCRPC), and metastatic renal cell carcinoma (RCC). The program highlights the importance of evidence-based approaches and the use of immunotherapy and targeted therapies for advanced genitourinary malignancies. Attendees will also explore emerging data that could influence future treatment guidelines, patient case examples, and insights from international faculty to develop region-specific therapeutic strategies aligned with NCCN recommendations.

CME credits: 1.25 Valid until: 20-12-2025 Claim your CME credit at https://reachmd.com/programs/cme/incorporation-of-guideline-recommendations-into-the-frontline-care-of-a-patient-with-mcrpc-who-is-naive-to-both-docetaxel-and-novel-hormone-therapy/29197/ This online CME activity, presented in collaboration with the National Comprehensive Cancer Network (NCCN®), focuses on translating oncology clinical practice guidelines into practical strategies for treating genitourinary malignancies. Participants will learn how to integrate clinical trial data into guideline-concordant first- and subsequent-line treatment plans for patients with metastatic urothelial cancer (UC), metastatic castration-resistant prostate cancer (mCRPC), and metastatic renal cell carcinoma (RCC). The program highlights the importance of evidence-based approaches and the use of immunotherapy and targeted therapies for advanced genitourinary malignancies. Attendees will also explore emerging data that could influence future treatment guidelines, patient case examples, and insights from international faculty to develop region-specific therapeutic strategies aligned with NCCN recommendations.

CME credits: 1.25 Valid until: 20-12-2025 Claim your CME credit at https://reachmd.com/programs/cme/guideline-recommended-first-line-treatment-with-immunotherapy-and-targeted-therapy-combinations-in-renal-cell-carcinoma/29198/ This online CME activity, presented in collaboration with the National Comprehensive Cancer Network (NCCN®), focuses on translating oncology clinical practice guidelines into practical strategies for treating genitourinary malignancies. Participants will learn how to integrate clinical trial data into guideline-concordant first- and subsequent-line treatment plans for patients with metastatic urothelial cancer (UC), metastatic castration-resistant prostate cancer (mCRPC), and metastatic renal cell carcinoma (RCC). The program highlights the importance of evidence-based approaches and the use of immunotherapy and targeted therapies for advanced genitourinary malignancies. Attendees will also explore emerging data that could influence future treatment guidelines, patient case examples, and insights from international faculty to develop region-specific therapeutic strategies aligned with NCCN recommendations.

CME credits: 1.25 Valid until: 20-12-2025 Claim your CME credit at https://reachmd.com/programs/cme/guideline-recommended-second-line-treatment-following-an-immune-checkpoint-inhibitor-in-renal-cell-carcinoma/29199/ This online CME activity, presented in collaboration with the National Comprehensive Cancer Network (NCCN®), focuses on translating oncology clinical practice guidelines into practical strategies for treating genitourinary malignancies. Participants will learn how to integrate clinical trial data into guideline-concordant first- and subsequent-line treatment plans for patients with metastatic urothelial cancer (UC), metastatic castration-resistant prostate cancer (mCRPC), and metastatic renal cell carcinoma (RCC). The program highlights the importance of evidence-based approaches and the use of immunotherapy and targeted therapies for advanced genitourinary malignancies. Attendees will also explore emerging data that could influence future treatment guidelines, patient case examples, and insights from international faculty to develop region-specific therapeutic strategies aligned with NCCN recommendations.

CME credits: 1.25 Valid until: 20-12-2025 Claim your CME credit at https://reachmd.com/programs/cme/emerging-targeted-therapy-combination-strategies-in-genitourinary-malignancies/29200/ This online CME activity, presented in collaboration with the National Comprehensive Cancer Network (NCCN®), focuses on translating oncology clinical practice guidelines into practical strategies for treating genitourinary malignancies. Participants will learn how to integrate clinical trial data into guideline-concordant first- and subsequent-line treatment plans for patients with metastatic urothelial cancer (UC), metastatic castration-resistant prostate cancer (mCRPC), and metastatic renal cell carcinoma (RCC). The program highlights the importance of evidence-based approaches and the use of immunotherapy and targeted therapies for advanced genitourinary malignancies. Attendees will also explore emerging data that could influence future treatment guidelines, patient case examples, and insights from international faculty to develop region-specific therapeutic strategies aligned with NCCN recommendations.

Host: Jacob Sands, MD Guest: Marina Garassino, MD Datopotamab deruxtecan (Dato-DXd) is a second-line antibody drug conjugate that could lead to improved progression-free survival in patients with advanced or metastatic non-small cell lung cancer. Given these potential benefits, it's important to identify biomarkers that may predict a patient's response to Dato-DXd, which was the focus of recent research presented at the 2024 World Conference on Lung Cancer. Here with Dr. Jacob Sands to discuss a new biomarker for TROP2 is Dr. Marina Garassino, Professor of Medicine and Director of the Thoracic Oncology Program at the University of Chicago.

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Hope S. Rugo, MD, FASCO While endocrine therapy (ET) and CDK4/6 inhibitors are the standard for treating ER+/HER2- metastatic breast cancer, patients can become resistant to ET. To overcome these resistance mechanisms, the ELEVATE study examines whether combining elacestrant with ET could help address this unmet need. Here to share the preliminary findings from ELEVATE with Dr. Charles Turck is lead study investigator Dr. Hope Rugo. She's also the Winterhof Distinguished Professor of Breast Oncology and the Director of Breast Oncology and Clinical Trials Education at the University of California, San Francisco Helen Diller Family Comprehensive Cancer Center.

CME credits: 0.75 Valid until: 30-08-2025 Claim your CME credit at https://reachmd.com/programs/cme/her2-testing-strategies-across-tumor-types-amidst-guidelines-gaps/26789/ This online MinuteCE program delves into the significance of HER2 as an actionable biomarker across various tumor types, emphasizing its implications for targeted therapies and clinical decision-making. Participants will evaluate emerging data on the efficacy of HER2-directed agents in advanced HER2-positive solid tumors and learn evidence-based strategies to monitor and mitigate treatment-related adverse events. Enhance your expertise so that you can optimize treatment adherence and improve patient outcomes.

CME credits: 0.75 Valid until: 30-08-2025 Claim your CME credit at https://reachmd.com/programs/cme/patient-case-how-do-her2-directed-therapies-fit-into-the-biliary-tract-cancer-treatment-landscape/26795/ This online MinuteCE program delves into the significance of HER2 as an actionable biomarker across various tumor types, emphasizing its implications for targeted therapies and clinical decision-making. Participants will evaluate emerging data on the efficacy of HER2-directed agents in advanced HER2-positive solid tumors and learn evidence-based strategies to monitor and mitigate treatment-related adverse events. Enhance your expertise so that you can optimize treatment adherence and improve patient outcomes.

CME credits: 0.75 Valid until: 30-08-2025 Claim your CME credit at https://reachmd.com/programs/cme/patient-case-how-do-her2-directed-therapies-fit-into-the-ovarian-cancer-treatment-landscape/26794/ This online MinuteCE program delves into the significance of HER2 as an actionable biomarker across various tumor types, emphasizing its implications for targeted therapies and clinical decision-making. Participants will evaluate emerging data on the efficacy of HER2-directed agents in advanced HER2-positive solid tumors and learn evidence-based strategies to monitor and mitigate treatment-related adverse events. Enhance your expertise so that you can optimize treatment adherence and improve patient outcomes.

CME credits: 0.75 Valid until: 30-08-2025 Claim your CME credit at https://reachmd.com/programs/cme/emerging-data-evaluating-her2-directed-therapies-in-gynecologic-cancers/26792/ This online MinuteCE program delves into the significance of HER2 as an actionable biomarker across various tumor types, emphasizing its implications for targeted therapies and clinical decision-making. Participants will evaluate emerging data on the efficacy of HER2-directed agents in advanced HER2-positive solid tumors and learn evidence-based strategies to monitor and mitigate treatment-related adverse events. Enhance your expertise so that you can optimize treatment adherence and improve patient outcomes.

CME credits: 0.75 Valid until: 30-08-2025 Claim your CME credit at https://reachmd.com/programs/cme/pivotal-data-on-targeting-her2-in-her2-expressing-solid-tumors/26791/ This online MinuteCE program delves into the significance of HER2 as an actionable biomarker across various tumor types, emphasizing its implications for targeted therapies and clinical decision-making. Participants will evaluate emerging data on the efficacy of HER2-directed agents in advanced HER2-positive solid tumors and learn evidence-based strategies to monitor and mitigate treatment-related adverse events. Enhance your expertise so that you can optimize treatment adherence and improve patient outcomes.

CME credits: 0.75 Valid until: 30-08-2025 Claim your CME credit at https://reachmd.com/programs/cme/diversity-in-her2-expression-among-gynecologic-cancers/26790/ This online MinuteCE program delves into the significance of HER2 as an actionable biomarker across various tumor types, emphasizing its implications for targeted therapies and clinical decision-making. Participants will evaluate emerging data on the efficacy of HER2-directed agents in advanced HER2-positive solid tumors and learn evidence-based strategies to monitor and mitigate treatment-related adverse events. Enhance your expertise so that you can optimize treatment adherence and improve patient outcomes.

CME credits: 0.75 Valid until: 30-08-2025 Claim your CME credit at https://reachmd.com/programs/cme/significance-of-her2-expression-in-solid-tumors/26788/ This online MinuteCE program delves into the significance of HER2 as an actionable biomarker across various tumor types, emphasizing its implications for targeted therapies and clinical decision-making. Participants will evaluate emerging data on the efficacy of HER2-directed agents in advanced HER2-positive solid tumors and learn evidence-based strategies to monitor and mitigate treatment-related adverse events. Enhance your expertise so that you can optimize treatment adherence and improve patient outcomes.